Pharmacokinetics, distribution and elimination of a synthetic octapeptide analogue of somatostatin in the rat.
The in vivo fate of a long acting somatostatin analogue [des-AA1,2,3,4,13,14,D-Trp8,Gaba12]-somatostatin has been studied in the rat using biochemical and autoradiographic techniques. The analogue has a longer plasma half-life than somatostatin. This is due to its greater metabolic stability which renders it resistant to enzymic attack in the tissues. The primary route of elimination is by biliary excretion following clearance from the circulation by the liver. Evidence of enterohepatic circulation was found, but only to a very limited extent. When administered s.c., high plasma concentrations of intact peptide persist for a period of hours due to slow release from a stable depot at the injection site.
D000818:Animals; D001345:Autoradiography; D001646:Bile / Q000378:metabolism; D006207:Half-Life; D007700:Kinetics; D008099:Liver / Q000378:metabolism; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000378:metabolism*; D013329:Structure-Activity Relationship; D014018:Tissue Distribution; D014316:Tritium
D014316:Tritium; D013004:Somatostatin; C033566:CGP 15425